This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeClinical InformationClinical InformationACIP RecommendationsWhat is TicoVacTM?What is TBE?Symptoms & Risk FactorsDemonstrated EffectivenessDosing & Administration SchedulePatient ResourcesOrder TicoVacTM
Prescribing Information Indication Patient Site
HCP Resources
It Can Take Just One Bite.

Tick-Borne Encephalitis (TBE) is a rare, but potentially devastating disease affecting the brain and spine.1 Help your patients, particularly travelers to Europe and Asia who may be at risk of infection with tick-borne encephalitis virus (TBEV).2 

Symptoms of TBE typically occur in 1/3 of those infected and can appear in 2 distinct phases.3 In the first phase, patients often present with flu-like symptoms of fever and headache while the second phase is characterized by central nervous system involvement with symptoms of meningitis.In rare cases, TBE viral infection can cause lifelong consequences, including disability and death.1,4

ACIP Provisional Recommendations

The CDC's Advisory Committee on Immunization Practices (ACIP) has unanimously voted to recommend the TBE vaccine for protection against TBE.5

For persons who travel or move to TBE endemic areas5:
  • TBE vaccine is recommended for persons who are moving or traveling to a TBE-endemic area and will have extensive exposure to ticks based on their planned outdoor activities and itinerary.
  • Additionally, TBE vaccine may be considered for persons traveling or moving to a TBE-endemic area who might engage in outdoor activities in areas ticks are likely to be found. The decision to vaccinate should be based on an assessment of their planned activities and itinerary, risk factors for a poorer medical outcome, and personal perception and tolerance of risk.

​​​​​​​​​​​​​​For laboratory workers: TBE vaccination is recommended for those with a potential exposure to the TBE virus (TBEV).5

ACIP recommendations are provisional until published in the Morbidity and Mortality Weekly Report (MMWR).

Read more from the CDC 
Loading
WHAT IS TICOVACTM?

TicoVacTM is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.6​​​​​​​

Find out about TicoVacTMLoading
WHAT IS TBE?

Tick-borne Encephalitis is a disease caused by a virus that can be spread by a bite from an infected tick or through consumption of unpasteurized dairy products.​​​​​​​2

Learn more about TBE Loading
SYMPTOMS & RISK FACTORS

Travelers spending time in wooded or grassy areas in many parts of Europe and Asia may be at risk for infection with tick-borne encephalitis virus (TBEV).2

Go to symptoms & risk factors Loading
DEMONSTRATED EFFECTIVENESS

TicoVacTM is >96% effective in preventing hospitalized TBE.6

Review effectivenessLoading
DOSING & ADMINISTRATION SCHEDULE

TicoVacTM primary dosing series should be completed at least 1 week prior to potential exposure to TBEV.6

Learn more about dosingLoading
MATERIALS FOR PATIENTS

Ensure your patients have all the facts.

Download patient materialsLoading
Contact your Pfizer Customer Service Representative at
​​​​​​​1-800-666-7248.

Already have a Pfizer Prime account?
Manage your account or place your order here.

References:​​​​​​​Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-1871. doi:10.1016/S0140-6736(08)60800-4Centers for Disease Control and Prevention. Tickborne Encephalitis. Travelers’ Health. Accessed February 9, 2022. https://wwwnc.cdc.gov/travel/diseases/tickborne-encephalitis.Fischer M, Gould CV, Rollin PE. Tickborne Encephalitis. CDC Yellow Book 2020: Health Information for International Travel. Oxford University Press; 2017. Chap 4. Accessed February 9, 2022. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/tickborne-encephalitis.Barrett PN, Portsmouth D, Ehrlich HJ. Tick-borne encephalitis virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Elsevier Saunders; 2013:773-788.
Vaccine. Tick-borne encephalitis (TBE). Centers for Disease Control and Prevention. Accessed April 5, 2022. https://www.cdc.gov/tick-borne-encephalitis/healthcare-providers/hcp-vaccine.html.
TicoVacTM (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

May 2022 PP-TCV-USA-0102
You are now leaving Pfizer
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
​​​​​​​
PP-TCV-USA-0102
INDICATION AND USAGE TicoVacTM is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.​​​​​​​
IMPORTANT SAFETY INFORMATION
  • TicoVacTM should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVacTM.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVacTM.
  • TicoVacTM may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVacTM.​​​​​​​
  • TicoVacTM contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).​​​​​​​
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVacTM were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVacTM were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
Patients should always ask their healthcare providers for medical advice about adverse events.
 
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.​​​​​​​
Please see full prescribing information for TicoVacTM here.
Indication TicoVacTM is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.